Genetically Engineered Mouse Models for TMEN Research

用于 TMEN 研究的基因工程小鼠模型

• 批准号: 8744892
• 负责人: LYNDA CHIN
• 金额: $ 9.11万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8744892
• 关键词: Accounting; Aftercare; Alleles; BRAF gene; Backcrossings; Biocompatible Materials; Biopsy; Breeding; Cell Line; Cells; Complement; Databases; Engineering; Epigenetic Process; Foundations; Genetic; Genetic Engineering; Genetically Engineered Mouse; Goals; Human; Image; Immunocompetent; Individual; Life; Location; Luciferases; Modeling; Mus; Relapse; Research; Resistance; Resources; Role; Sampling; Scheme; Sorting - Cell Movement; Source; Therapeutic; Therapeutic Studies; Tissue Banking; Tissue Banks; Tissues; Tumor Bank; Tumor Cell Line; Validation; arm; cell type; cohort; design; genetic element; inhibitor/antagonist; meetings; melanocyte; melanoma; mouse model; novel; pre-clinical; preclinical study; research study; resistance mechanism; response; tumor; tumor microenvironment; validation studies

Core B will provide a constant resource of mice harboring melanomas that express BRAF*, including pairs of tumor biopsies that are sensitive or resistant to BRAFi. The integrative power of this core lies in interacting and intersecting with parallel samples from human melanomas in Core A, providing cross-species triangulation of genetic elements that confer tumor microenvironment-specific phenotypic effects. This core will provide not only a bank of Braf* mouse (iBIP and M3) melanoma tissues and derivative cell lines collected at baseline, post-treatment and upon relapse, but also capability to engineer new alleles ex vivo and perform preclinical therapeutic studies. The immunocompetent background and natural tumor microenvironment setting of IBIP melanomas bring a key feature to this TMEN center.

核心B将提供持续的携带黑色素瘤的小鼠资源 BRAF*，包括对Brafi敏感或抗性的肿瘤活检对。的综合力量 该核心在于相互作用并与来自人类黑色素瘤的平行样品相互作用， 提供赋予肿瘤微环境特异性的遗传因素的跨物种三角剖分 表型效应。该核心不仅将提供BRAF*小鼠（IBIP和M3）黑色素瘤组织 以及在基线，治疗后和复发后收集的衍生细胞系，但也有能力 工程新等位基因在体内并进行临床前治疗研究。免疫能力 IBIP黑色素瘤的背景和天然肿瘤微环境设置为此带来了关键特征 TMEN中心。